• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

EBioMedicine . Distinct lung cell signatures define the temporal evolution of diffuse alveolar damage in fatal COVID-19

tetano

Editor, Senior Moderator
EBioMedicine


. 2023 Dec 23:99:104945.
doi: 10.1016/j.ebiom.2023.104945. Online ahead of print. Distinct lung cell signatures define the temporal evolution of diffuse alveolar damage in fatal COVID-19

Luke Milross[SUP] 1 [/SUP], Bethany Hunter[SUP] 2 [/SUP], David McDonald[SUP] 2 [/SUP], George Merces[SUP] 2 [/SUP], Amanda Thomson[SUP] 3 [/SUP], Catharien M U Hilkens[SUP] 1 [/SUP], John Wills[SUP] 4 [/SUP], Paul Rees[SUP] 5 [/SUP], Kasim Jiwa[SUP] 6 [/SUP], Nigel Cooper[SUP] 6 [/SUP], Joaquim Majo[SUP] 6 [/SUP], Helen Ashwin[SUP] 7 [/SUP], Christopher J A Duncan[SUP] 8 [/SUP], Paul M Kaye[SUP] 7 [/SUP], Omer Ali Bayraktar[SUP] 9 [/SUP], Andrew Filby[SUP] 10 [/SUP], Andrew J Fisher[SUP] 11 [/SUP]



Affiliations
Free article Abstract

Background: Lung damage in severe COVID-19 is highly heterogeneous however studies with dedicated spatial distinction of discrete temporal phases of diffuse alveolar damage (DAD) and alternate lung injury patterns are lacking. Existing studies have also not accounted for progressive airspace obliteration in cellularity estimates. We used an imaging mass cytometry (IMC) analysis with an airspace correction step to more accurately identify the cellular immune response that underpins the heterogeneity of severe COVID-19 lung disease.
Methods: Lung tissue was obtained at post-mortem from severe COVID-19 deaths. Pathologist-selected regions of interest (ROIs) were chosen by light microscopy representing the patho-evolutionary spectrum of DAD and alternate disease phenotypes were selected for comparison. Architecturally normal SARS-CoV-2-positive lung tissue and tissue from SARS-CoV-2-negative donors served as controls. ROIs were stained for 40 cellular protein markers and ablated using IMC before segmented cells were classified. Cell populations corrected by ROI airspace and their spatial relationships were compared across lung injury patterns.
Findings: Forty patients (32M:8F, age: 22-98), 345 ROIs and >900k single cells were analysed. DAD progression was marked by airspace obliteration and significant increases in mononuclear phagocytes (MnPs), T and B lymphocytes and significant decreases in alveolar epithelial and endothelial cells. Neutrophil populations proved stable overall although several interferon-responding subsets demonstrated expansion. Spatial analysis revealed immune cell interactions occur prior to microscopically appreciable tissue injury.
Interpretation: The immunopathogenesis of severe DAD in COVID-19 lung disease is characterised by sustained increases in MnPs and lymphocytes with key interactions occurring even prior to lung injury is established.
Funding: UK Research and Innovation/Medical Research Council through the UK Coronavirus Immunology Consortium, Barbour Foundation, General Sir John Monash Foundation, Newcastle University, JGW Patterson Foundation, Wellcome Trust.

Keywords: COVID-19; Diffuse alveolar damage; Imaging mass cytometry; Immunopathology; Post-mortem lung tissue.

 
Back
Top Bottom